CLINICAL ROLE -
Long-Acting Injectable Form of Cabotegravir Safe for HIV Prevention in Pregnant Cisgender Women
An extension of a long-acting cabotegravir study shows safety prior to and during pregnancy in cisgender women, with full results being presented at the 2024 International AIDS Conference.
Twice-Yearly Lenacapavir Effective in Significantly Reducing HIV Infections in Cisgender Women
Adherence and efficacy were both higher in patients with HIV who took twice-yearly lenacapavir compared to those on oral preexposure prophylaxis medication.
